GlaxoSmithKline plc (LON:GSK) has been assigned an average rating of “Hold” from the twenty-three brokerages that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is GBX 1,551.90 ($21.44).
A number of brokerages recently commented on GSK. Liberum Capital reiterated a “buy” rating and set a GBX 1,760 ($24.32) price objective on shares of GlaxoSmithKline in a research report on Wednesday, October 25th. Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($24.87) price objective on shares of GlaxoSmithKline in a research report on Monday, October 23rd. UBS Group set a GBX 1,550 ($21.41) price objective on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Thursday, February 8th. Credit Suisse Group set a GBX 1,300 ($17.96) price objective on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Thursday, February 8th. Finally, Societe Generale reiterated a “sell” rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th.
In related news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.10), for a total transaction of £262,000 ($361,978.45). Also, insider Sir Roy Anderson bought 562 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were bought at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Insiders have purchased a total of 590 shares of company stock valued at $754,966 over the last three months.
The company also recently disclosed a dividend, which will be paid on Thursday, April 12th. Stockholders of record on Thursday, February 22nd will be paid a GBX 23 ($0.32) dividend. The ex-dividend date is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous dividend of $19.00. This represents a dividend yield of 1.78%.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/14/glaxosmithkline-plc-gsk-receives-average-recommendation-of-hold-from-analysts.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.